Product Description
Chemical Name: Maxacalcitol
- CAS No.103909-75-7
- Molecular Formula:C26H42O4
- Formula Weight:418.617
Synonyms:1,3-Cyclohexanediol,4-methylene-5-[(2E)-[(1S,3aS,7aS)-octahydro-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-4H-inden-4
AI Product Description
*The following content is generated by AI and is for reference only.
Maxacalcitol, identified by CAS number 103909-75-7, is a potent synthetic vitamin D analog widely utilized in pharmaceutical research and clinical therapeutics. With a purity level of 99% GMP (Good Manufacturing Practice), this high-quality intermediate serves as a critical building block for the development of advanced dermatological and metabolic treatments. The molecular formula of Maxacalcitol is C28H46O3, corresponding to its chemical structure as 1,25-dihydroxy-22-oxa-vitamin D3. This specific structural modification enhances its biological activity while significantly reducing calcemic side effects compared to native 1,25-dihydroxyvitamin D3.
The primary application of Maxacalcitol lies in the management of hyperparathyroidism associated with chronic renal failure and the treatment of psoriasis. As a non-calcemic analog, it effectively regulates cell proliferation and differentiation, making it invaluable for inhibiting the rapid skin cell turnover characteristic of psoriatic lesions. In the pharmaceutical supply chain, materials meeting 99% GMP standards are essential for ensuring patient safety and regulatory compliance during drug formulation. These specifications guarantee consistency, sterility, and rigorous quality control, which are mandatory for manufacturing injectable solutions or topical creams intended for human use.
Furthermore, Maxacalcitol plays a pivotal role in academic and industrial research focusing on bone metabolism, calcium homeostasis, and oncology. Scientists utilize this compound to investigate receptor binding affinities and signaling pathways related to the vitamin D receptor (VDR). Its stability and efficacy make it a preferred choice for preclinical studies aiming to develop next-generation therapies with improved therapeutic indices. Manufacturers emphasizing DMF (Drug Master File) status provide comprehensive documentation, facilitating faster approval processes for downstream drug developers. By adhering to strict GMP protocols, suppliers ensure that every batch delivers optimal performance, supporting global efforts to treat complex endocrine disorders and autoimmune skin conditions efficiently. Ultimately, Maxacalcitol represents a cornerstone in modern pharmacotherapy, bridging the gap between biochemical research and effective clinical intervention.
(All Rights Reserved)
